Amin Gharbi-Meliani1, Aline Dugravot1, Séverine Sabia1, Melina Regy1, Aurore Fayosse1, Alexis Schnitzler1, Mika Kivimäki2, Archana Singh-Manoux1,2, Julien Dumurgier3,4. 1. Université de Paris, Inserm U1153, Epidemiology of Ageing and Neurodegenerative Diseases, Paris, France. 2. Department of Epidemiology and Public Health, University College London, London, UK. 3. Université de Paris, Inserm U1153, Epidemiology of Ageing and Neurodegenerative Diseases, Paris, France. julien.dumurgier@inserm.fr. 4. Cognitive Neurology Center, Lariboisiere - Fernand Widal Hospital, AP-HP, Université de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris, France. julien.dumurgier@inserm.fr.
Abstract
BACKGROUND: Approximately 25% of the general population carries at least one ε4 allele of the Apolipoprotein E (APOE ε4), the strongest genetic risk factor for late onset Alzheimer's disease. Beyond its association with late-onset dementia, the association between APOE ε4 and change in cognition over the adult life course remains uncertain. This study aims to examine whether the association between Apolipoprotein E (APOE) ε4 zygosity and cognition function is modified between midlife and old age. METHODS: A cohort study of 5561 participants (mean age 55.5 (SD = 5.9) years, 27.1% women) with APOE genotyping and repeated cognitive tests for reasoning, memory, and semantic and phonemic fluency, during a mean (SD) follow-up of 20.2 (2.8) years (the Whitehall II study). We used joint models to examine the association of APOE genotype with cognitive function trajectories between 45 and 85 years taking drop-out, dementia, and death into account and Fine and Gray models to examine associations with dementia. RESULTS: Compared to non-carriers, heterozygote (prevalence 25%) and homozygote (prevalence 2%) APOE ε4 carriers had increased risk of dementia, sub-distribution hazard ratios 2.19 (95% CI 1.73, 2.77) and 5.97 (95% CI 3.85, 9.28) respectively. Using data spanning 45-85 years with non-ε4 carriers as the reference, ε4 homozygotes had poorer global cognitive score starting from 65 years; ε4 heterozygotes had better scores between 45 and 55 years, then no difference until poorer cognitive scores from 75 years onwards. In analysis of individual cognitive tests, better cognitive performance in the younger ε4 heterozygotes was primarily attributable to executive function. CONCLUSIONS: Both heterozygous and homozygous ε4 carriers had poorer cognition and greater risk of dementia at older ages. Our findings show some support for a complex antagonist pleiotropic effect of APOE ε4 heterozygosity over the adult life course, characterized by cognitive advantage in midlife.
BACKGROUND: Approximately 25% of the general population carries at least one ε4 allele of the Apolipoprotein E (APOE ε4), the strongest genetic risk factor for late onset Alzheimer's disease. Beyond its association with late-onset dementia, the association between APOE ε4 and change in cognition over the adult life course remains uncertain. This study aims to examine whether the association between Apolipoprotein E (APOE) ε4 zygosity and cognition function is modified between midlife and old age. METHODS: A cohort study of 5561 participants (mean age 55.5 (SD = 5.9) years, 27.1% women) with APOE genotyping and repeated cognitive tests for reasoning, memory, and semantic and phonemic fluency, during a mean (SD) follow-up of 20.2 (2.8) years (the Whitehall II study). We used joint models to examine the association of APOE genotype with cognitive function trajectories between 45 and 85 years taking drop-out, dementia, and death into account and Fine and Gray models to examine associations with dementia. RESULTS: Compared to non-carriers, heterozygote (prevalence 25%) and homozygote (prevalence 2%) APOE ε4 carriers had increased risk of dementia, sub-distribution hazard ratios 2.19 (95% CI 1.73, 2.77) and 5.97 (95% CI 3.85, 9.28) respectively. Using data spanning 45-85 years with non-ε4 carriers as the reference, ε4 homozygotes had poorer global cognitive score starting from 65 years; ε4 heterozygotes had better scores between 45 and 55 years, then no difference until poorer cognitive scores from 75 years onwards. In analysis of individual cognitive tests, better cognitive performance in the younger ε4 heterozygotes was primarily attributable to executive function. CONCLUSIONS: Both heterozygous and homozygous ε4 carriers had poorer cognition and greater risk of dementia at older ages. Our findings show some support for a complex antagonist pleiotropic effect of APOE ε4 heterozygosity over the adult life course, characterized by cognitive advantage in midlife.
Authors: Xiaoyan Sun; Chuanhui Dong; Bonnie Levin; Elizabeth Crocco; David Loewenstein; Henrik Zetterberg; Kaj Blennow; Clinton B Wright Journal: Alzheimers Dement Date: 2016-06-16 Impact factor: 21.566
Authors: Alexandra J Weigand; Kelsey R Thomas; Katherine J Bangen; Graham M L Eglit; Lisa Delano-Wood; Paul E Gilbert; Adam M Brickman; Mark W Bondi Journal: Alzheimers Dement Date: 2020-09-04 Impact factor: 21.566
Authors: Christian R A Mondadori; Dominique J-F de Quervain; Andreas Buchmann; Henrietta Mustovic; M Axel Wollmer; Conny F Schmidt; Peter Boesiger; Christoph Hock; Roger M Nitsch; Andreas Papassotiropoulos; Katharina Henke Journal: Cereb Cortex Date: 2006-10-31 Impact factor: 5.357
Authors: Sebastian Palmqvist; Michael Schöll; Olof Strandberg; Niklas Mattsson; Erik Stomrud; Henrik Zetterberg; Kaj Blennow; Susan Landau; William Jagust; Oskar Hansson Journal: Nat Commun Date: 2017-10-31 Impact factor: 14.919
Authors: Mark James Rawle; Daniel Davis; Rebecca Bendayan; Andrew Wong; Diana Kuh; Marcus Richards Journal: Transl Psychiatry Date: 2018-01-10 Impact factor: 6.222
Authors: Jaisalmer de Frutos-Lucas; Pablo Cuesta; David López-Sanz; África Peral-Suárez; Esther Cuadrado-Soto; Federico Ramírez-Toraño; Belinda M Brown; Juan M Serrano; Simon M Laws; Inmaculada C Rodríguez-Rojo; Juan Verdejo-Román; Ricardo Bruña; Maria L Delgado-Losada; Ana Barabash; Ana M López-Sobaler; Ramón López-Higes; Alberto Marcos; Fernando Maestú Journal: Alzheimers Res Ther Date: 2020-04-24 Impact factor: 6.982